DK1020462T3 - Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens - Google Patents

Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens

Info

Publication number
DK1020462T3
DK1020462T3 DK98933922T DK98933922T DK1020462T3 DK 1020462 T3 DK1020462 T3 DK 1020462T3 DK 98933922 T DK98933922 T DK 98933922T DK 98933922 T DK98933922 T DK 98933922T DK 1020462 T3 DK1020462 T3 DK 1020462T3
Authority
DK
Denmark
Prior art keywords
active ingredient
heterocyclic compounds
agents containing
tumor agents
tumor
Prior art date
Application number
DK98933922T
Other languages
English (en)
Inventor
Seiichiro Kawashima
Toshiyuki Matsuno
Shinichi Yaguchi
Tetsuo Watanabe
Masahiro Inaba
Original Assignee
Zenyaku Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo Kk filed Critical Zenyaku Kogyo Kk
Application granted granted Critical
Publication of DK1020462T3 publication Critical patent/DK1020462T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
DK98933922T 1997-07-24 1998-07-24 Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens DK1020462T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19880497 1997-07-24
PCT/JP1998/003308 WO1999005138A1 (fr) 1997-07-24 1998-07-24 Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs

Publications (1)

Publication Number Publication Date
DK1020462T3 true DK1020462T3 (da) 2004-04-26

Family

ID=16397198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933922T DK1020462T3 (da) 1997-07-24 1998-07-24 Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens

Country Status (11)

Country Link
US (1) US6251900B1 (da)
EP (1) EP1020462B1 (da)
JP (1) JP4276376B2 (da)
KR (1) KR100563514B1 (da)
CN (1) CN1129597C (da)
AU (1) AU727013B2 (da)
CA (1) CA2297326C (da)
DE (1) DE69821633T2 (da)
DK (1) DK1020462T3 (da)
ES (1) ES2213286T3 (da)
WO (1) WO1999005138A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143157A0 (en) 1998-11-17 2002-04-21 Kumiai Chemical Industry Co Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides
AU3078000A (en) * 1999-01-25 2000-08-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agents containing the same as the active ingredient
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
DK1183245T3 (da) 1999-04-22 2007-09-24 Lundbeck & Co As H Selektive NPY(Y5)-antagonister
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
CA2445395C (en) 2001-04-27 2010-03-30 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent comprising the same as effective component
ES2389253T3 (es) * 2002-10-25 2012-10-24 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo
EP2316831B1 (en) * 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
US20050107374A1 (en) * 2003-10-21 2005-05-19 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2561406C (en) * 2004-03-31 2012-07-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
JP2008538544A (ja) * 2004-09-23 2008-10-30 レディ ユーエス セラピューティックス， インコーポレイテッド 新規ピリミジン化合物、それらの調製のためのプロセスおよびそれらを含む組成物
WO2006095906A1 (ja) * 2005-03-11 2006-09-14 Zenyaku Kogyo Kabushikikaisha 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090270390A1 (en) * 2006-09-14 2009-10-29 Astrazeneca Pyrimidine derivatives
WO2008032036A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090233926A1 (en) * 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
AU2008213808B2 (en) * 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
US8163748B2 (en) * 2007-05-23 2012-04-24 New York University s-Triazine compounds, pharmaceutical compositions and method of using the same
EP2409975B1 (en) 2007-11-22 2015-05-27 Zenyaku Kogyo Kabushikikaisha Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
EP3216793B1 (en) 2008-05-23 2019-03-27 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
KR20110120286A (ko) 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
MX2011010105A (es) 2009-03-27 2012-01-12 Pathway Therapeutics Inc Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
AR080945A1 (es) * 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
UA108390C2 (uk) 2010-08-10 2015-04-27 Астеллас Фарма Інк. Похідні бензімідазолу та їх застосування
RU2608742C2 (ru) 2011-03-28 2017-01-23 ЭмИАй ФАРМА, ИНК. (альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
CA2849995A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN104245693B (zh) * 2012-12-14 2016-08-24 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
CN105175410B (zh) * 2015-10-14 2018-01-05 湖南华腾制药有限公司 三嗪类化合物及其制备方法和抗肿瘤应用
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
WO2019036489A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. COMBINATION THERAPY
CN112047938B (zh) * 2019-06-06 2022-11-22 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948776A (ja) * 1994-09-26 1997-02-18 Dai Ichi Seiyaku Co Ltd ピリミジニルピラゾール誘導体

Also Published As

Publication number Publication date
EP1020462A4 (en) 2003-01-08
DE69821633D1 (de) 2004-03-18
WO1999005138A1 (fr) 1999-02-04
KR20010021860A (ko) 2001-03-15
CN1129597C (zh) 2003-12-03
EP1020462B1 (en) 2004-02-11
JP4276376B2 (ja) 2009-06-10
AU727013B2 (en) 2000-11-30
DE69821633T2 (de) 2004-12-16
ES2213286T3 (es) 2004-08-16
EP1020462A1 (en) 2000-07-19
CA2297326C (en) 2007-03-20
KR100563514B1 (ko) 2006-03-27
CA2297326A1 (en) 1999-02-04
CN1271355A (zh) 2000-10-25
US6251900B1 (en) 2001-06-26
AU8357598A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
DK1020462T3 (da) Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
IS5058A (is) Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DK1028961T3 (da) Pleuromutilinderivater som antimikrobielle midler
ID22878A (id) Komposisi aktif secara terapi
DK1015434T3 (da) Ny pyrimidin-4-on og pyrimidin-4-thion som fungicid
NO20000048L (no) Triazolforbindelser og deres anvendelse som dopamin-D3- ligander
DK1062217T3 (da) Herbicidt aktive 3-hydroxy-4-aryl-5-oxopyrazolinderivater
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
NO980546D0 (no) Farmasöytiske midler
NO982296L (no) Triaromatiske forbindelser, preparater inneholdende disse og deres anvendelse
DE69823360D1 (de) Feste arzneizubereitung enthaltend benzofuranderivate
NO984106D0 (no) Azolobenzazepin-derivater som neurologisk aktive midler
NO308294B1 (no) Dimetyl-3(aryl-but-3-enyl)-aminforbindelse som farmasøytiske forbindelser og anvendelse av disse
NO996584D0 (no) brukshjelp for absorberende gjenstand til engangsbruk
DE69805807D1 (de) Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
NO981121L (no) Substituerte aminoforbindelser og deres anvendelse som analgetisk virksomme stoffer
NO20006646L (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
NO20000366D0 (no) O-substituerte hydroksycoumaranon-derivater som anti-tumor- og antimetastase-midler
NO20013318L (no) Substituerte 2-aryliminoheterocykliske forbindelser og preparater inneholdende disse for anvendelse
NO973471D0 (no) Transdermal formulering
DK0868911T3 (da) Rapamycinpræparater til oral indgivelse
NO973715D0 (no) Transdermal formulering